Plain-English translation of NCT06180590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing Vosevi, a newer hepatitis C medication that contains three active ingredients, to see if it works better than an older two-part medication for people whose first hepatitis C treatment didn't fully work. Hepatitis C is a serious virus that can damage your liver over time, and many patients can now be cured with medication—but some people need a second treatment when the first one doesn't completely clear the virus. This study will help doctors understand which treatment works best for those patients.
Most people with hepatitis C can be cured with antiviral medications, but some patients don't respond to their first treatment and need a different approach. There isn't much data yet on how well this medication works in Asian patients, so this study aims to fill that gap and help doctors choose the best second-line treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take one of two hepatitis C treatments by mouth: either the newer three-part medication taken once daily, or the older two-part medication taken once daily plus an additional medication twice daily. You will need to take your assigned treatment regularly and likely visit the hospital for blood tests to check whether the virus has been cleared and to monitor your liver health. The study will track how well the treatment works and compare the two approaches to help doctors decide which is better for patients like you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China